Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexeo Therapeutics (LXEO) Preferred Stock Liabilities (2022 - 2023)

Historic Preferred Stock Liabilities for Lexeo Therapeutics (LXEO) over the last 2 years, with Q3 2023 value amounting to $185.0 million.

  • Lexeo Therapeutics' Preferred Stock Liabilities changed 0.0% to $185.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $185.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $185.0 million for FY2022, which is N/A changed from last year.
  • According to the latest figures from Q3 2023, Lexeo Therapeutics' Preferred Stock Liabilities is $185.0 million, which was down 0.0% from $185.0 million recorded in Q4 2022.
  • Over the past 5 years, Lexeo Therapeutics' Preferred Stock Liabilities peaked at $185.0 million during Q3 2022, and registered a low of $185.0 million during Q3 2022.